Genfleet Therapeutics (shanghai) Inc.
Clinical trials sponsored by Genfleet Therapeutics (shanghai) Inc., explained in plain language.
-
New pill takes on tough pancreatic cancer in major trial
Disease control Recruiting nowThis study tests a new daily pill, GFH375, against standard chemotherapy in 320 people with advanced pancreatic cancer that has a specific KRAS G12D gene mutation. Participants must have already tried at least one standard treatment. The goal is to see if the new drug helps peopl…
Phase: PHASE3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for hard-to-treat cancers: targeted combo therapy enters trials
Disease control Recruiting nowThis study tests a new drug (GFH375) combined with either cetuximab or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the combination is safe and can shrink tumors. About 126 adults who have not responded to standa…
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for Hard-to-Treat cancers: targeted drug enters human trials
Disease control Recruiting nowThis study tests an experimental drug called GFH375 in people with advanced solid tumors that have a specific genetic change (KRAS G12D). The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 407 adults aged 18 to 75 with advanced cancers like lung or pa…
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC